Pseudomyxoma peritonei is a rare disease characterized by diffuse gelatinous ascites and mucinous tumor implants throughout the peritoneal cavity. It is usually caused by the rupture of a mucin-producing tumor, often originating from the appendix. Diagnosis is typically made through CT imaging and surgical exploration. Treatment involves aggressive cytoreductive surgery to remove all visible tumor deposits combined with hyperthermic intraperitoneal chemotherapy to address any remaining microscopic disease. This multimodal approach has improved long-term survival rates compared to surgery alone, with some reports of 80% 10-year survival when all tumor nodules can be completely resected.

1. Hamed Rashad
Professor of surgery Banha faculty of medicine
Pseudomyxoma Peritonei and
Mucocele

2. Appendiceal Cancer
• 1% of appendectomies contain cancer
– 2/3 carcinoid (50% all GI carcinoids are appendiceal)
• Tan-yellow mass, surrounding desmoplastic reaction
• < 2 cm  no further treatment
• > 2 cm  R hemicolectomy
– Remainder: mucinous cystadenocarcinoma,
adenocarcinoma, adenocarcinoid
– Adenocarcinoma associated with metastatic disease
50% of time (likely 2nd appendiceal rupture, tumor
spread)

4. Appendiceal mucocele
• Dilated, mucin-filled appendix
• 0.3% of all appendectomies
• 4 histologic categories:
1) Retention cyst = simple mucocele (normal mucosa)
2) Mucosal hyperplasia
3) Mucinous cystadenoma (~ papillary adenoma of colon)
4) Mucinous cystadenocarcinoma
Contemporary Surgery, 2002; 58 (12), 609-613

5. Mucoceles: pathophysiology
• Obstruction of appendiceal lumen 
dilation with mucin
– Obstruction 2nd hyperplasia or fecalith
• Presentation depends on nature/degree of
obstruction:
– Slow, chronic  large mucocele formation
– Fecalith  acute inflammation, with mucinous
content

6. Mucoceles: natural history
• Asymptomatic (25%), vs. chronic RLQ
pain vs. acute appendicitis
• Mucocele can also lead to:
– Bowel obstruction 2nd intussusception  cecum
– Torsion  gangrenous appendix
– Rupture  mucinous ascites, pseudomyxoma
peritonei
– Risk factor for colon cancer (synchronous,
metachronous)

9. Differential Diagnosis
• Duplication cyst
• Mesenteric/omental cyst
• Ovarian cyst
• Periappendiceal abscess

11. Mucoceles: treatment
• Hyperplasia, mucinous cystadenoma
treated by simple appendectomy
• Malignant mucocele:
– Preop/intraop suspicion  R hemicolectomy,
or appendectomy and frozen section
– Post-op diagnosis  return for definitive
procedure

12. Pseudomyxoma peritonei

13. Introduction
• The Pseudomyxoma Peritonei is a rare
disease characterized by diffusion of a
gelatinous ascites whether associated or
not to mucinous implants in the peritoneal
cavity.
• It’s secondary to the rupture in the
peritoneal cavity of some mucinoid tumors
whose the origin is frequently appendiceal.

14. Pseudomyxoma Peritonei
• Extremely rare; 300 cases/yr in U.S.
• Diffuse, intraperitoneal collection of gelatinous
fluid with mucinous tumor implants on peritoneal
surfaces and omentum
• Strictly, etiology is 2nd grade I mucinous
cystadenocarcinoma of the appendix
• Ovarian, pancreatic cancer  similar picture

15. Epidemiology
• 2-3 times commoner in males than females
• Median ages at diagnoses 51-61 years old
• Present in 2 0ut of 10,000 laparotomy

16. PMP : Classification
• DPAM (Disseminated Peritoneal AdenoMucineses)
-- Abundant extracellular mucin
-- Little cytological atypia
• PMCA (Peritoneal Mucinous Carcinomatoses)
-- Carcinomatous cytologic features
• PMCA-I (Peritoneal Mucinous Carcimatoses-
Intemediate or discordant features)
-- Focal area of mucinous carcinoma
Ronnett, BM, et al., cancer,2001-92:85

17. Pathophysiology
• Mucocele rupture  dissemination of mucin-
producing tumor cells throughout peritoneal
cavity
• Characteristic and predictable pattern of tumor
progression:
1) Gravity  dependent collection of tumor
(pelvis, retrohepatic space, paracolic gutters, Treitz)
2) Resorption of peritoneal fluid  accumulation of
tumor cells to distinct sites:
Sugarbaker, PA. Histopathology 2001; 39, 525-528.

18. Deposit Sites 2nd Fluid Resorption
1) Between liver, R hemidiaphragm
-2nd lymphatics within undersurface of
hemidiaphragm
2) Greater, lesser omentum
-lymphatics draw fluid, attracting tumor
cells to their surface  omental caking
Sugarbaker, PA. Histopathology 2001; 39, 525-528

19. PMP : Clinical picture
• Symptoms
* Abdominal or pelvic pain , bloating , distension
* Digestive disorders
* Weight changes
* Infertility
• Presentation
* Suspected appendicitis (27%)
* Increasing abdominal distension (23%)
* A new onset hernia (14%)
• Diagnosed in women while evaluated for ovarian mass

20. Clinical picture
Circumstances of discovery:
• Alteration of the general state
• Abdominal distension
• Abdominal pains
• Constipation and vomiting: 6 cases.
• Eventration
Clinical exam:
• Perception of one or several abdominal masses
• Abdominal dullness
• Bulging of the Douglas' pouch

21. Ultrasonography
Echogenic ascites Septated ascites

22. Cystic hepatic and splenic ascites
Hepatic Splenic

23. PMP : Diagnoses
• CT :
• Central displacement
of the small bowel and
compression of
retroperitoneal
structures
• Peritoneal cavity full of
PMP

24. CT
Peritoneal calcifications

25. CT
Scalloping phenomenon on the liver and
spleen

26. Scalloping phenomenon on the liver and
spleen

27. Peritoneal cavity with mucinous tumor in the pelvis

28. CT
Hepatic (a) and splenic (b) cystic metastasis

29. CT
Appendiceal mucocele (AM)
(AM)
AM

30. CT
Right ovarian tumor (T)
Right ovarian solido
cystic mass (M)
(T) M

34. Pseudomyxoma peritpnii
Bowel wall thickening and
fold swelling
Multiple non-enhancing
intraperitoneal masses

35. CT before cntrast

36. CT post-contrast

37. Corresponding finding on laparotomy to previous CT

38. CT

43. Workup
• CT-guided aspiration of pelvic fluid
• Analysis: mucinous adenocarcinoma
• Taken to OR for exploratory laparoscopy

44. Treatment
• Traditional Surgical Treatment
– Consists of
• Cytoreductive surgery
• Removal of all mucinous ascites
• ± Additional modalities
– Long-term survival could not be achieved
by surgery alone

45. Surgery
– Aggressive cytoreductive surgery
• Parietal peritonectomy
– Greater omentectomy
– Splenectomy
– Stripping of the left diaphragm and the
right diaphragm

46. Surgery
• – Cholecystectomy
• – Lesser omentectomy
• – Antrectomy
• – Pelvic peritonectomy
• – Resection of recto-sigmoid and internal
gynecological organs
• • Hyperthermic intraperitoneal
chemotherapy (HIPEC)

47. Surgery
– Concentration of disease in ileo-cecal region
• Ileo-cecum resection or a right hemicolectomy
• Ileum might be anastomosed or brought out as a
ileostomy
– Greater omentectomy
• Ligation of the gastric branches in the (right) gastric
arcade
• Contribute blood supply to stomach and left gastric
artery not be able to sustain adequate gastric blood flow.
• Results in gastric paresis and postoperative ileus
Therefore, gastrostomy and a high jejunostomy for
gastric emptying and nutrition.

48. Chemotherapy
• Hyperthermic intraperitoneal chemotherapy
(HIPEC)
– Direct delivery into the peritoneal cavity
– Permits high concentrations of drugs directly
toward the tumor deposits
– Without important systemic side effects
– Hyperthermia enhance the penetration of
cytostatic drugs and synergism with various
cytostatic drugs
– Effective only in minimal residual macroscopic
disease because of the limited penetration depth

49. – Chemotherapeutic agents
• Doxorubicin (15mg/m2)
• Melphalan
• Mitomycin-C (12mg/m2)
• Cisplatin (50mg/m2)
• Gemcitabine
• Mitoxantrone
• Oxaliplatin
• Etoposide
• Irinotecan
• Paclitaxel
• Docetaxel
• 5-Fuorouracil (500 mg/m2)
• Carboplatin

50. – Carriers of chemotherapeutic agents
• Isotonic salt solutions and dextrose solutions
– Rapid absorption
– Inability to maintain a prolonged high
intraperitoneal fluid volume
–Most commonly used
• Hypotonic solutions
– Cisplatin accumulates in tumor cells &
enhances its cytotoxicity
– High incidence of unexplained postoperative
peritoneal bleeding with oxaloplatin

51. – Duration for perfusion
• 410C x 90 min
• 430C x 30–40 min
• 420C x 60 min
– Complications
• 30-45%
• Chemotherapy toxicity to kidneys, bone
marrow, liver,
lungs- 2-5%
• Organ damage secondary to hyperthermia
• Surgical complications – 25-30%
– Small bowel fistula
• Moratlity - 0-5%

53. Other treatment modality
– Laparoscopic approach
• • allows thorough exploration of the
abdomen
• • irrigation and aspiration of the thick
mucinous material, and the instillation of
mucolytic agents, 5% dextrose solution.

54. – Should be performed intra-operatively before
anastomoses,
to maximize uniform drug distribution and tumor exposure
Los G et al. Cancer Res 1992;52:1252-8
– In h/o prior surgery, adhesiolysis should be performed to
prevent nonuniform drug distribution
• All microscopic tumor residue is not eliminated
• Lead to recurrent disease
– Mitomycin as an intraperitoneal drug, either as single drug
or in combination
van Ruth S et al. Surg Oncol Clin N Am 2003;12:771-80.

55. HIPC
– Two techniques
• Open
– Small bowel floats in drug solution
• Closed
– No loss of heat or drug
– Entire peritoneum is exposed
– Allow administration of drug under
pressure

56. Sugarbaker Protocol
• Radical debulking of tumor load:
– appendix, peritoneum, omentum;
– additional viscera as indicated
– Curative therapy = all nodules > 2.5 mm
• Intraoperative heated mitomycin (44c)
• Post-operative 5-FU
• Reports of 80% 10 yr survival

57. Gelatinous material on exploration
and after evacuation

58. Laparoscopic view : showing gelatinous
material on peritoneal surface

59. Operation
• Rt hemicolectomy
• Harman’ procedure
• Debulking of tumour

60. – Mucinous tumor on parietal peritoneum
• Resection by high-power electrocautery with a
balltipped handpiece on high voltage pure cut

61. PMP : Treatment – Perioperative loco
regional chemotherapy (PLC)
HIPEC --- Hyper
thermic intra-operative
chemo therapy
EPIC --- Early post-
operative intra peritoneal
chemotherapy
Commonly used
agents
* Mitomycin
* Cisplatin, 5-FU

62. Further
• Other reports have 5-year survival of 50-
75%
• CEA, CA 19-9 of some use in surveillance
• Laparoscopic treatment reported by select
institutions (Cleveland Clinic)

63. Summary
• The Pseudomyxoma Peritonei is a dangerous
complication of the mucinous tumors dominated by the
appendiceal origin.
• the medical imaging is fundamental in the diagnosis and
the surveillance of this rare pathology. US permits a
better characterization of the ascites whereas the CT
visualizes the calcifications and the scalloping effect.
• A good knowledge of its particularities
physiopathological and radiological by the physician
radiologist is important to put in guard the surgeon.

64. Summary
• incidence is 2 per million per year with an unexplained
female dominance
• Redistribution phenomenon predicts location It is thought
to be peritoneal disseminated disease from a primary
appendiceal mucinous epithelial neoplasm unless (very
rarely) proven otherwise with a normal appendix and a
primary tumor elsewhere
• It is suspected in case of intraperitoneal mucus with
cellular content, found during laparotomy or at physical
examination (abdominal girth)
• combination of (aggressive) surgical debulking with
peritonectomy and hyperthermic intraperitoneal
chemotherapy seems to improve the outcome.

65. Summary
• • Patients with high-grade disease (peritoneal
mucinous carcinomatosis), disease extent with
more than 5 involved abdominal regions, and/or
small bowel involvement should receive
palliative treatment because they do not benefit
from aggressive treatment approaches

66. PMP : Summary
• Cytoreductive surgery with/without intra-
peritoneal chemotherapy may be the best
treatment strategy for PMP
• Surgery should be done to remain no or
minimal residual tumour

67. THANK YOU